Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Bernstein Keeps Their Hold Rating on Moderna (MRNA)

Tipranks - Tipranks - Wed Apr 22, 7:38AM CDT

In a report released today, Courtney Breen from Bernstein maintained a Hold rating on Moderna, with a price target of $45.00.

Claim 30% Off TipRanks

Breen covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Moderna, and Merck & Company. According to TipRanks, Breen has an average return of 15.3% and an 81.25% success rate on recommended stocks.

In addition to Bernstein, Moderna also received a Hold from Oppenheimer’s Jay Olson in a report issued yesterday. However, on the same day, Bank of America Securities maintained a Sell rating on Moderna (NASDAQ: MRNA).

See today’s best-performing stocks on TipRanks >>

Based on Moderna’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $678 million and a GAAP net loss of $826 million. In comparison, last year the company earned a revenue of $956 million and had a GAAP net loss of $1.12 billion

Read More on MRNA:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).